YS Biopharma Announces Leadership Changes
Ticker: LSBWF · Form: 6-K · Filed: Mar 5, 2024 · CIK: 1946399
| Field | Detail |
|---|---|
| Company | Ys Biopharma CO., LTD. (LSBWF) |
| Form Type | 6-K |
| Filed Date | Mar 5, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, subsidiary-management, foreign-private-issuer
TL;DR
YS Biopharma shakes up its Chinese subsidiary leadership, filing March 5th.
AI Summary
YS Biopharma Co., Ltd. announced board changes and strategic leadership appointments in its Chinese subsidiaries on March 5, 2024. The company, formerly known as YishengBio Co., Ltd., is incorporated in E9 and has its fiscal year end on March 31. The filing was made under the 1934 Act with SEC file number 001-41598.
Why It Matters
Changes in leadership can signal shifts in company strategy or operational focus, potentially impacting future performance and investor outlook.
Risk Assessment
Risk Level: low — This filing is a routine report of foreign private issuer and does not contain significant financial or operational disclosures that would immediately impact risk.
Key Players & Entities
- YS Biopharma Co., Ltd. (company) — Registrant
- YishengBio Co., Ltd. (company) — Former company name
- March 5, 2024 (date) — Filing date
- 001-41598 (other) — SEC File Number
FAQ
What specific board changes and leadership appointments were made?
The filing indicates Exhibit 99.1 contains a press release detailing these changes, but the content of the press release is not provided in this excerpt.
When did the company change its name from YishengBio Co., Ltd.?
The company changed its name from YishengBio Co., Ltd. on September 12, 2022.
What is the fiscal year end for YS Biopharma Co., Ltd.?
The fiscal year end for YS Biopharma Co., Ltd. is March 31.
Under which SEC Act is this filing made?
This filing is made under the Securities Exchange Act of 1934.
What is the primary business of YS Biopharma Co., Ltd. according to its SIC code?
According to its Standard Industrial Classification (SIC) code, the company is involved in Pharmaceutical Preparations [2834].
Filing Stats: 220 words · 1 min read · ~1 pages · Grade level 9.4 · Accepted 2024-03-05 08:06:33
Filing Documents
- ea0201209-6k_ysbiopharma.htm (6-K) — 10KB
- ea0201209ex99-1_ysbiopharma.htm (EX-99.1) — 6KB
- ex99-1_001.jpg (GRAPHIC) — 7KB
- 0001213900-24-019749.txt ( ) — 27KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. YS Biopharma Co., Ltd. Date: March 5, 2024 By: /s/ Hui Shao Name: Hui Shao Title: Director and Chief Executive Officer 2